A phase i pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers

Anesthesia and Analgesia

Volumn 115, Issue 3, 2012, Pages 554-559

  Lim, Chin Beng Stephen ^a,b   Schug, Stephan A ^c,d   Bruce Sunderland, Vivian ^b   Paech, Michael James ^c,e   Liu, Yandi ^c  

^a Armadale Health Service   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL CITRATE; NALTREXONE; POLYPROPYLENE;

ADULT; ARTICLE; BLOOD SAMPLING; BURNING SENSATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; FEMALE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; VOLUNTEER;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; FENTANYL; HUMANS; MALE; YOUNG ADULT;

EID: 84865685406     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3182575cbf     Document Type: Article

References (30)

1. Hagen N, Stiles C, Nekolaichuk C, Biondo P, Carlson L, Fisher K, Fainsinger R. The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manage 2008;35:136-52
2. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008;35:563-7
3. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic noncancer pain. BMJ 2001;322:1154-8
4. Gourlay GK, Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2001;2:165-72
5. Mather LE, Woodhouse A, Ward ME, Stephen J, Farr JS, Rubsamen AR, Lorne G, Eltherington LG. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol 1998;46:37-43
6. Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157-60
7. Blick SKA, Wagstaff AJ. Fentanyl buccal tablets in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006;66:2387-93
8. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010;11:1017-23
9. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343-50
10. Stanley TH, Hague B, Mock DL, Streisand JB, Bubbers S, Dzelzkalns RR, Bailey PL, Pace NL, East KA, Ashburn MA. Oral transmucosal fentanyl citrate (lollipop) premedication in human volunteers. Anesth Analg 1989;69:21-7
11. Christie J, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, Portenoy RK. Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-45
12. Streisand JB, Varvel JR, Stanski DR, Le Maire L, Ashburn MA, Hague BI, Tarver SD, Stanley TH. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991;75,223-9
13. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Inghan J, Loseth B, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-12
14. Striebel HW, Kramer J, Luhman I, Rohierse-Hohler I, Rieger A. Pharmacokinetics of intranasal fentanyl (in German). Schmerz 1993;7:122-5
15. Lim SCB, Paech M, Sunderland VB, Roberts M, Banks S, Rucklidge M. Pharmacokinetics of nasal fentanyl. J Pharm Prac Res 2003;33:59-63
16. Mercadante S, Radbruck L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin 2009;25:2805-15
17. Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manage 2010;6:17-26
18. Bredenberg S, Duberg M, Lennernas B, Lennernäs H, Pettersson A, Westerberg M, Nyström C. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Euro J Pharm Sci 2003;20:327-34
19. Lennernäs B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med 2010;24:286-93
20. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11
21. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34
22. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:588-601
23. Gardner-Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. J Pain Symptom Manage 2001;22:627-30
24. Rathbone MJ, Hadgraft J. Absorption of drugs from the human oral cavity. Int J Pharm 1991;74:9-24
25. Aronoff G, Brennan M, Pritchard D, Ginsberg B. Evidencebased oral transmucosal fentanyl citrate (OTFC) dosing guide lines. Pain Med 2005;6:305-14
26. Zhang H, Zhang J, Streisand J. Oral mucosal drug delivery clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002;41:661-80
27. Ghosh TK, Pfister WR. Drug delivery to the oral cavity. Boca Raton: CRC Press, 2005
28. Shojaei A. Buccal mucosa as a route for systemic drug delivery. J Pharm Pharm Sci 1998;1:15-30
29. Lim CB, Paech MJ, Sunderland VB, Liu Y. A pilot pharmacokinetic study of a sublingual fentanyl wafer in adult postoperative patients. (In press)
30. Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, Lennernas H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2004;59:249-53